Aura Biosciences (AURA) EBT (2020 - 2026)

Aura Biosciences has reported EBT for 7 years, with the latest figure at -$33.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 22.61% year-over-year to -$33.7 million; the trailing twelve-month figure through Mar 2026 stood at -$112.3 million (down 19.47% YoY), and the FY2025 full-year result was -$106.1 million, down 23.09% from the prior year.
• EBT for Q1 2026 stood at -$33.7 million, down from -$25.5 million in the prior quarter.
• The five-year high for EBT was -$12.8 million in Q1 2022, with the low at -$33.7 million in Q1 2026.
• Historically, EBT has averaged -$21.3 million across 5 years, with a median of -$20.3 million in 2024.
• Annual changes were most pronounced in 2022 — EBT plunged 116.15% — and 2025, when it dropped 1.41%.
• Aura Biosciences' EBT stood at -$17.6 million in 2022, then fell by 24.87% to -$22.0 million in 2023, then dropped by 14.52% to -$25.2 million in 2024, then retreated by 1.41% to -$25.5 million in 2025, then sank by 31.83% to -$33.7 million in 2026.
• The last three EBT figures came in at -$33.7 million (Q1 2026), -$25.5 million (Q4 2025), and -$26.1 million (Q3 2025), per Business Quant data.